EPO Patent Bulletin - Biotech (C12N)

Selective Targeting of Host CD70+ Alloreactive Cells to Prolong Allogeneic CAR T Cell Persistence

The European Patent Office published patent application EP4355358A1 on April 8, 2026, filed by Allogene Therapeutics, Inc. The invention covers methods for selectively targeting host CD70+ alloreactive cells to enhance persistence of allogeneic CAR-T cells for therapeutic use. The patent is designated across multiple European member states including Germany, France, and the United Kingdom.

Lyophilized ENPP1 Polypeptide Formulations and Uses Thereof

The European Patent Office published patent application EP4404980A1 for BioMarin Pharmaceutical Inc., covering lyophilized ENPP1 polypeptide formulations and their therapeutic uses. The patent application was filed with multiple IPC classifications including A61K (pharmaceutical preparations), C12N (enzymes/nucleic acids), and C07K (peptides). The application designates all European member states.

EP4301859A1 - Enhanced Targeting Using Antibody-Oligonucleotide Conjugates

The European Patent Office has published patent application EP4301859A1 for Code Biotherapeutics, Inc. and University of Maryland, College Park, covering enhanced targeting technology using antibody-oligonucleotide conjugates. The patent application was published on April 8, 2026, with inventors Muro, Roki, and Getts. Designated states include all EU contracting states for potential validation.

Lipid Nanoparticle Stem Cell Therapeutics - European Patent EP4330391A1

The European Patent Office granted Patent EP4330391A1 to the Trustees of the University of Pennsylvania for compositions and methods targeting lipid nanoparticle therapeutics to stem cells. The patent covers IPC classifications including A61K 47/69, A61K 47/68, A61K 9/51, C12N 15/88, and A61K 48/00. The patent is valid in 35 designated European member states including Germany, France, the United Kingdom, Italy, and Spain.

Engineered CasX Repressor Systems, EP4405479A2

The European Patent Office published application EP4405479A2 for Engineered CasX Repressor Systems filed by Scribe Therapeutics Inc. The patent covers engineered CasX proteins with repressive functionality for gene expression control. The application has been published designating 31 European states including major markets DE, FR, GB, NL, SE, and CH.

AstraZeneca Complement C3 Inhibitor Patent Application EP4326876A1

The European Patent Office published AstraZeneca patent application EP4326876A1 for compositions and methods inhibiting complement component 3 expression. The application names AstraZeneca Ireland Limited as applicant with inventors including Lasaro, Melissa and McKnight, Susan. Designated states cover all EPC contracting states including Germany, France, UK, Italy, Spain, and others.

University of Washington Muscle Gene Regulatory Cassettes Patent Application EP4319874A2

The European Patent Office published patent application EP4319874A2 for University of Washington covering artificial regulatory cassettes for muscle-specific gene expression. The application names inventors Jeffrey S. Chamberlain and Stephen D. Hauschka. The patent is classified under IPC codes related to genetic engineering and pharmaceutical preparations for muscular disorders.

Mitochondria-Enriched Cell Identification, EP4281579A1

The European Patent Office published patent application EP4281579A1, filed by Minovia Therapeutics Ltd., covering methods for identifying mitochondria-enriched cells. The application designates 39 states including all EU member states plus CH, LI, MC, TR, and GB. The invention relates to C12N cell classification and G01N detection methods with applications in cell therapy.

RNA-Based Control of Powdery Mildew - Greenlight Biosciences EP4304353A2

EPO published patent application EP4304353A2 by Greenlight Biosciences Inc. for RNA-based control of powdery mildew, a fungal disease affecting plants. The application covers double-stranded RNA compositions and methods for controlling fungal pathogens in agriculture. The patent designation extends across 38 European member states including Germany, France, and the United Kingdom.

Tumor Infiltrating Lymphocytes Therapy

The European Patent Office published patent application EP4329782A1 for Alethia Biotherapeutics ULC covering tumor infiltrating lymphocytes (TIL) therapy for cancer treatment. The application includes 17 IPC classifications including cell compositions, antibodies, and combination therapies. The patent designates 35 European states including Germany, France, UK, Italy, Spain, and the Netherlands.

Antisense Oligomer EP4342498A1, Chiba University, published 8th Apr

The European Patent Office published patent application EP4342498A1 for an antisense oligomer therapeutic developed by National University Corporation Chiba University. The patent covers antisense oligomer compositions, gene therapy vectors, and pharmaceutical formulations with therapeutic applications in cardiovascular, metabolic, dermatological, and other disease areas. The granted rights apply across the designated Contracting States including EU member states, CH, GB, NO, TR, and others.

EP4347847A1 - Flexible Expression Vector Systems for Vaccines and Immunotherapeutics

The European Patent Office granted patent EP4347847A1 to The University of British Columbia and The James Hutton Institute. The patent covers flexible expression vector systems and their applications in vaccines and immunotherapeutics, with inventors Jefferies and Ribeca. The patent is designated across 31 European member states.

Lentiviral Vectors Patent - Oxford BioMedica (UK) Limited EP4118217A1

The European Patent Office published patent application EP4118217A1 for Oxford BioMedica (UK) Limited covering lentiviral vectors (IPC C12N 15/86). Jordan Wright is listed as the inventor. The patent designates all listed European member states including DE, FR, GB, IT, ES, NL, BE, CH, and others. Patent grants provide exclusive commercial rights to the holder.

EP4127152A1 - Methods for Identifying Genomic DNA Bound to Protein

EPO published patent application EP4127152A1 for Altius Institute for Biomedical Sciences and The Brigham & Women's Hospital, Inc. The invention covers methods, compositions, and kits for identifying regions of genomic DNA bound to a protein. The application was published under the A1 publication kind code on April 8, 2026.

PCSK9 Antagonist Patent Application by Argonaute RNA Limited

The European Patent Office published application EP4081642A1 for Argonaute RNA Limited, covering RNA-based antagonists of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9). Inventors are Daniel Mitchell and Michael Khan. The patent is classified under IPC C12N 15/113 and designates all contracting states of the European Patent Convention.

EP4139921A1 - Method and System for Identifying Candidate Immunogenic Protein Regions for Vaccine Development

The European Patent Office published application EP4139921A1 for NEC OncoImmunity AS, covering a computational method and system for identifying candidate regions of source proteins predicted to instigate an immunogenic response. The invention has applications in vaccine development and creates enforceable patent rights across 36 designated European member states.

Boosting Homology Directed Repair in Plants (EP4172340A1)

The EPO has granted patent EP4172340A1 to KWS SAAT SE & Co. KGaA for methods of boosting homology directed repair in plants. The patent application (C12N 15/82) was published on April 8, 2026, with inventor Yu Mei. This establishes intellectual property rights in designated European states for agricultural biotechnology applications.

Anti-TIGIT Antibodies and Usage Method

The European Patent Office published patent application EP4089115A1 titled 'Anti-TIGIT Antibodies and Usage Method' filed by Shanghai Henlius Biotech, Inc. The patent covers anti-TIGIT antibodies and their usage methods, classified under C07K 16/28 with applications in cancer treatment (A61P 35/00). The application designates 34 European member states including DE, FR, GB, IT, ES, NL, and CH.

Soluble ENPP1 or ENPP3 Proteins and Uses Thereof

The European Patent Office published application EP4162036A1 for BioMarin Pharmaceutical Inc. and Yale University covering soluble ENPP1 or ENPP3 proteins and their uses. The patent application was published April 8, 2026 with A1 designation (first publication with European search report). The application designates all European contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Hydrogels Cultured Meat Production Patent EP4100445A1

The European Patent Office granted Patent EP4100445A1 to Mosa Meat B.V. for hydrogels used in cultured meat production. The invention covers biomaterial compositions (C08B 37/00, C08L 5/04) and methods for culturing animal cells (C12N 5/00, C12N 5/077). The patent is valid in 31 designated contracting states including major markets across the EU, UK, Switzerland, Norway, and Turkey.

Bisdemethoxycurcumin Compositions for Managing Chronic Obstructive Pulmonary Disease (EP4090340A1)

The European Patent Office published patent application EP4090340A1, filed by Sami-Sabinsa Group Limited, covering compositions comprising bisdemethoxycurcumin for managing chronic obstructive pulmonary disease (COPD). The patent names Muhammed Majeed, Kalyanam Nagabhushanam, Sarang Bani, and Anjali Pandey as inventors. The application is classified under A61K 31/12 (ketone-based therapeutic compositions) with designations across 37 European contracting states including all EU member states.

Pancreatic Cancer Detection Kit - Toray Industries

The European Patent Office published application EP3988668A2 for a kit and method detecting early-stage pancreatic cancer and precursor lesions. Applicants are Toray Industries, Inc. and the National Cancer Center. The application covers all EPC contracting states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR). The technology uses genetic detection methods classified under C12Q 1/68.

Helix Biopharma Corp. Antibody-Urease Conjugates for Diagnostic and Therapeutic Use

The European Patent Office granted Patent EP2984170A1 to Helix Biopharma Corp. for antibody-urease conjugates for diagnostic and therapeutic purposes. The patent, with inventor Chao Heman, covers compositions classified under A61K 47/68, A61P 35/00, C07K 16/32, C12N 9/80, and C12N 9/96. The designated states include all EU member states and extension countries.

Anti-HER3 Antibody Drug Conjugate Patent by Beijing Sinotau Bio-Pharma

EPO published patent application EP4355787A1 for Anti-HER3 antibody drug conjugate compositions and methods by Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. The patent covers ADC technology targeting HER3 for cancer treatment with designated states spanning major European jurisdictions. Inventors include Zhong Xiaoyan, Li Zhe, and Zhu Jie.

BASF SE Patents Wheat G-Type Cytoplasmic Male Sterility Restorer Genes

The European Patent Office published patent application EP3429335A1 on April 8, 2026, granting BASF SE exclusive rights to wheat G-type cytoplasmic male sterility restorer genes, molecular markers, and related uses. The patent covers biotechnology applications in plant breeding under IPC classifications C12Q, C07K, C12N, and A01H across all designated EPO member states.

DNA Editing Using Single-Stranded DNA - EP3303585A1 Patent Grant

The European Patent Office published patent grant EP3303585A1 for DNA editing using single-stranded DNA. The patent names Board of Regents of the University of Nebraska and Tokai University Educational System as applicants. The invention covers biotechnology methods for DNA editing with applications in genetic research and development.

City of Hope Patents Phosphorothioated Oligodeoxynucleotide Compounds and Compositions

The European Patent Office published patent application EP3316894A1 for City of Hope covering phosphorothioated oligodeoxynucleotide compounds and pharmaceutical compositions for therapeutic use. The application classifies under IPC codes C12N 15/113 and A61K 31/713 relating to oligonucleotides and nucleic acid preparations. The publication establishes a priority date and makes the application available for opposition.

Use of Cellulase to Improve Viscosity Control of Dissolving Pulp

The European Patent Office published patent application EP3365493A1 by Novozymes A/S for the use of cellulase enzymes to improve viscosity control of dissolving pulp. The patent covers methods of treating pulp with cellulase to achieve desired viscosity characteristics in paper manufacturing processes. The application was published April 8, 2026.

Microbial Consortia Patent Application EP3262152A1

The European Patent Office published patent application EP3262152A1 for Amvac Chemical Corporation, covering microbial consortia compositions and their applications in agriculture and chemical processing. The patent application includes claims for biological preparations, organic fertilizers, and related compositions. The designated states cover most European countries including DE, FR, GB, ES, IT, NL, and others.

Modified Adeno-Associated Virus Capsid Patent EP4389880A1

The European Patent Office published patent application EP4389880A1 for Joint Stock Company Biocad, covering methods of obtaining modified adeno-associated virus (AAV) capsids. The patent is classified under IPC codes C12N 7/00, C12N 15/86, C07K 14/005, and others related to viral vectors and genetic engineering. The patent designates all relevant European contracting states including Germany, France, Italy, Spain, and the United Kingdom.

Microbial Consortia Patent EP3262151A1, Amvac Chemical Corporation

The European Patent Office published patent application EP3262151A1 titled 'Microbial Consortia' filed by Amvac Chemical Corporation. The patent relates to compositions and methods involving microbial consortia, classified under IPC C12N (microorganisms, fungi, algae), C05F (fertilizers), and A01N (biocides). The patent application designates all EU member states.

Plants Comprising Wheat G-Type Cytoplasmic Male Sterility Restorer Genes, Molecular Markers and Uses Thereof

The European Patent Office granted BASF SE Patent EP3429334A1 covering wheat plants comprising G-type cytoplasmic male sterility restorer genes and associated molecular markers. The patent is classified under IPC codes A01H, C12N, and C07K, covering biotechnology applications for plant genetics. The designation includes 31 states across the EU and beyond.

Synthetic CAR-T Cells for Treating IL13Ra2 Positive Human and Canine Tumors

The European Patent Office published patent application EP4021464A1 (A1 kind, April 8, 2026) for synthetic CAR-T cells targeting IL13Ra2 positive tumors in humans and canines. Applicant is The Trustees of The University of Pennsylvania. Inventors include O'ROURKE, Donald M., YIN, Yibo, JOHNSON, Laura, BINDER, Zev, and THOKALA, Radhika. The patent covers compositions and methods for treating IL13Ra2-positive tumors using synthetic chimeric antigen receptor T-cells.

Gene Therapy for Alzheimer's Disease - Brigham and Women's Hospital EP3976637

The European Patent Office published patent application EP3976637A1, filed by The Brigham and Women's Hospital, Inc. and The General Hospital Corporation, covering a gene therapy approach for treating Alzheimer's disease. The invention, developed by inventors Shen Jie and Kelleher III Raymond J., is classified under C12N 15/86 and related protein classification C07K 14/47. The patent is designated across all EU member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Roche Oligonucleotides for Paternal UBE3A Expression

The European Patent Office published patent application EP3798307A1 for F. Hoffmann-La Roche AG covering oligonucleotides designed to induce paternal UBE3A expression. The invention relates to nucleic acid therapeutics targeting UBE3A gene expression, with applications in treating genetic disorders. The patent application was filed under IPC classification C12N 15/113 and designates all 39 contracting states across the European Patent Convention.